Rapport Therapeutics Inc Quick Ratio (RAPP) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rapport Therapeutics Inc   (NASDAQ: RAPP)

Rapport Therapeutics Inc 's Quick Ratio

RAPP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 15.34 a new company low.

Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Quick Ratio than Rapport Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 132 to 266.

Explain Quick Ratio?
How much Cash & cash equivalents RAPP´s has?
What are RAPP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RAPP Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 139.28 % 90.74 % 117.28 % 101.66 % 46.74 %
Y / Y Cash & cash equivalent Change 67.43 % 67.07 % 60.68 % 59.99 % -22.52 %
Quick Ratio MRQ 15.34 26.64 25.75 35.84 21.92
RAPP's Total Ranking # 266 # 132 # 76 # 56 # 108
Seq. Current Liabilities Change 58.82 % -6.05 % 33.06 % 20.52 % 26.6 %
Seq. Cash & cash equivalent Change -8.54 % -2.8 % -4.38 % 96.98 % -8.74 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 97
Overall Market # 266


Quick Ratio Statistics
High Average Low
45.17 29.56 15.34
(Sep 30 2024)   (Jun 30 2026)




Financial Statements
Rapport Therapeutics Inc 's Current Liabilities $ 28 Millions Visit RAPP's Balance sheet
Rapport Therapeutics Inc 's Cash & cash equivalent $ 436 Millions Visit RAPP's Balance sheet
Source of RAPP's Sales Visit RAPP's Sales by Geography


Cumulative Rapport Therapeutics Inc 's Quick Ratio

RAPP's Quick Ratio for the trailling 12 Months

RAPP Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 114.63 % 89.36 % 70.21 % 90.1 % 128.79 %
Y / Y Cash & cash equivalent TTM Growth 63.55 % 39.55 % 39.64 % 69.61 % 142.29 %
Quick Ratio TTM 24.05 27.57 28.36 30.76 31.56
Total Ranking TTM # 2777 # 2594 # 1693 # 1658 # 1928
Seq. Current Liabilities TTM Growth 26.2 % 15.59 % 23.19 % 19.44 % 11.35 %
Seq. Cash & cash equivalent TTM Growth 10.09 % 12.35 % 13.58 % 16.42 % -6.07 %

Quick ratio ranking by company, industry and sector >> Back to RAPP Financial Strength Comparisons >> Go to Compare RAPP Quick Ratio to its Competitors

  News about Rapport Therapeutics Inc Quick Ratio

Advancements in Seizure Biomarkers Insights from Rapport Therapeutics’ Phase 2a and Preclinical Trials

Rapport Therapeutics recently announced plans to present data at the American Epilepsy Society Annual Meeting, focusing on the outcomes of their Phase 2a trial, as well as preclinical and Phase 1 clinical data associated with seizure biomarkers. This article aims to outline the key findings and implications of these studies, which may provide significant advancements in the management and understanding of epilepsy. Epilepsy remains a complex neurological disorder affecting millions worldwide, characterized by recurrent seizures and significant comorbidity. Continuous efforts in research and development aim to identify reliable biomarkers for seizures, which can improve treatment protocols and patient management. Rapport Therapeutics has undertaken a rigorous approach to investigating such biomarkers, with recent announcements highlighting their upcoming presentations at the American Epilepsy Society Annual Meeting.

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2026 to $28.42 millions, cumulative Quick Ratio decreased to 24.05 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 401 other companies have achieved higher Quick Ratio than Rapport Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2594 to 2777.

Explain Quick Ratio?
How much Cash & cash equivalents RAPP´s has?
What are RAPP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 402
Healthcare Sector # 791
Within the Market # 2777


trailing twelve months Quick Ratio Statistics
High Average Low
37.41 30.51 24.05
(Mar 31 2025)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Trevi Therapeutics Inc   36.50 $ 318.870  Millions$ 8.736  Millions
Design Therapeutics Inc   35.76 $ 401.889  Millions$ 11.240  Millions
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Neuphoria Therapeutics Inc   26.26 $ 19.866  Millions$ 0.757  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions

Date modified: 2026-09-10T17:17:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.